Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Bob Mintzer"'
Autor:
Deborah Chen, Damian O. Arnaiz, Wei-Wei Li, Feldman Richard, James M. Wu, Marc Whitlow, Shendong Yuan, Mike Ferrer, Brad Buckman, Judi Bryant, Mark A. Polokoff, Daguang Zhu, Bob Mintzer, Zheng Chang, Kumar Emayan, Sandra L. Biroc, Harald Dinter, Xue Snow Ge, Jih-Lie Tseng, Marc Adler, Jian-Ming Gu, Takashi Sato, Jun Shen
Publikováno v:
Chemical biologydrug design. 74(1)
Heat-shock protein-90 is an attractive target for anticancer drugs, as heat-shock protein-90 blockers such as the ansamycin 17-(allylamino)-17-demethoxygeldanamycin greatly reduce the expression of many signaling molecules that are disregulated in ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ba5a3e56f10ef89bd5c9c6bebd1899e
https://pubmed.ncbi.nlm.nih.gov/19519743
https://pubmed.ncbi.nlm.nih.gov/19519743
Autor:
Doug Schneider, Silke Finster, Alicia Newton, Rick Lin, David Vogel, Pam Toy, Bob Mintzer, Marc Whitlow, Gordon Parry, Jian Ai Xuan, Qingyu Wu, Ying Zhu, Mark Polokoff, Harald Dinter, Renate Parry, David R. Light
Publikováno v:
Cancer research. 66(7)
Hepsin is a type II transmembrane serine protease that is expressed in normal liver, and at lower levels in kidney, pancreas, and testis. Several studies have shown that hepsin mRNA is significantly elevated in most prostate tumors, as well as a sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92d9a818b8e96563ceb2c08d5fa1ef53
https://pubmed.ncbi.nlm.nih.gov/16585186
https://pubmed.ncbi.nlm.nih.gov/16585186